Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Ciardiello, F. [3 ]
Seitz, J. -F. [4 ]
Hofheinz, R. D. [5 ]
Verma, U. [6 ]
Garcia-Carbonero, R. [7 ]
Grothey, A. [8 ]
Miriyala, A. [9 ]
Kalmus, J. [10 ]
Shapiro, J. [11 ]
Falcone, A. [12 ]
Zaniboni, A. [13 ]
机构：
[1] Univ Hosp Leuven, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Univ Naples 2, Dept Expt & Clin Med & Surg, Naples, Italy
[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Dept Digest Oncol, Marseille, France
[5] Heidelberg Univ, Univ Med Mannheim, Interdisziplinaren Tumorzentrum, Mannheim, Germany
[6] Univ Texas SW Med Ctr Dallas, Div Hematol & Oncol, Dallas, TX 75390 USA
[7] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain
[8] Mayo Clin, Dept Oncol, Rochester, NY USA
[9] Bayer Pharma AG, Global Pharmacovigilance & Risk Management, Berlin, Germany
[10] Bayer Pharma AG, Global Clin Dev Oncol Ophthalmol & Neurol, Berlin, Germany
[11] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA
[12] Univ Pisa, Dept Med Oncol, Pisa, Italy
[13] Fdn Poliambulanza, Dept Oncol, Brescia, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140O
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] ASPECCT: A RANDOMISED, MULTICENTRE, OPEN-LABEL, PHASE 3 STUDY OF PANITUMUMAB VS CETUXIMAB FOR PREVIOUSLY-TREATED WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC)
    Price, Tim J.
    Peeters, Marc
    Kim, Tae W.
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Atilli S.
    Zhang, Kathy
    Murugappan, Swaminathan
    Sidhu, Roger
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 73 - 73
  • [22] Results from a phase 3B, open-label, multicenter, continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Analysis by age group
    Chowdary, P.
    Mullins, E.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2019, 25 : 158 - 159
  • [23] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Carlos R. Becerra
    Ramon Salazar
    Rocio Garcia-Carbonero
    Anne L. Thomas
    Federico J. Vázquez-Mazón
    James Cassidy
    Tim Maughan
    Manuel Gallén Castillo
    Tim Iveson
    Donghua Yin
    Stephanie Green
    Emily K. Bergsland
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 695 - 702
  • [24] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Becerra, Carlos R.
    Salazar, Ramon
    Garcia-Carbonero, Rocio
    Thomas, Anne L.
    Vazquez-Mazon, Federico J.
    Cassidy, James
    Maughan, Tim
    Gallen Castillo, Manuel
    Iveson, Tim
    Yin, Donghua
    Green, Stephanie
    Bergsland, Emily K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 695 - 702
  • [25] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
    Price, T. J.
    Burge, M.
    Chantrill, L.
    Chua, Y. J.
    Horvath, L.
    McLachlan, S-A.
    Pavlakis, N.
    Shapiro, J.
    Thavaneswaran, S.
    Tran, B.
    Yip, D.
    Tancock, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1283 - S1283
  • [26] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
  • [27] Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
    Sonpavde, Guru P.
    Sternberg, Cora N.
    Loriot, Yohann
    Marabelle, Aurelien
    Lee, Jae Lyun
    Flechon, Aude
    Roubaud, Guilhem
    Pouessel, Damien
    Zagonel, Vittorina
    Calabro, Fabio
    Banna, Giuseppe L.
    Shin, Sang Joon
    Vera-Badillo, Francisco E.
    Powles, Thomas
    Hellmis, Eva
    Miranda, Paulo A. P.
    Lima, Ana Rita
    Emeribe, Ugochi
    Oh, Sun Min
    Hotte, Sebastien J.
    EUROPEAN JOURNAL OF CANCER, 2022, 163 : 55 - 65
  • [28] Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
    Bozzarelli, S.
    Rimassa, L.
    Giordano, L.
    Sala, S.
    Tronconi, M. C.
    Baretti, M.
    Personeni, N.
    Pressiani, T.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] DENOSUMAB IN PATIENTS WITH METASTATIC PROSTATE CANCER PREVIOUSLY TREATED WITH DENOSUMAB OR ZOLEDRONIC ACID: 2-YEAR OPEN-LABEL EXTENSION PHASE RESULTS FROM THE PIVOTAL PHASE 3 STUDY
    Fizazi, K.
    Brown, J. E.
    Carducci, M.
    Shore, N. D.
    Sieber, P.
    Kueppers, F.
    Karsh, L.
    Wei, R.
    Goessl, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 309 - 309
  • [30] A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
    Kotani, Daisuke
    Yamaguchi, Kensei
    Kato, Ken
    Hara, Hiroki
    Miura, Akinori
    Satoh, Taroh
    Komine, Keigo
    Kunisaki, Chikara
    Yabusaki, Hiroshi
    Hagiwara, Akiko
    Suzuki, Noriko
    Toyoizumi, Kiichiro
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Knoblauch, Roland Elmar
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 363 - 363
12345